- Home
- MNKD
MNKD
MannKind Corporation
as 05-30-2025 1:38pm EST
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | DANBURY |
| Market Cap: | 1.4B | IPO Year: | 2004 |
| Target Price: | $9.40 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.10 | EPS Growth: | 228.27 |
| 52 Week Low/High: | $4.05 - $7.63 | Next Earning Date: | 05-08-2025 |
| Revenue: | $297,595,000 | Revenue Growth: | 32.50% |
| Revenue Growth (this year): | 14.36% | Revenue Growth (next year): | 13.36% |
Stock Insider Trading Activity of MannKind Corporation (MNKD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Thomson David | MNKD | EVP Genl Counsel & Secretary | May 19 '25 | Sell | $4.41 | 2,345 | $10,341.45 | 879,546 | |
| Binder Steven B. | MNKD | Director | May 10 '25 | Sell | $4.69 | 80,144 | $375,875.36 | 1,006,611 |
Latest MannKind Corporation News
MNKD Breaking Stock News: Dive into MNKD Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
GlobeNewswire
17 days ago
MannKind to Present at Upcoming Investor Conferences
Simply Wall St.
20 days ago
MannKind First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Insider Monkey
21 days ago
MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain
MT Newswires
22 days ago
MannKind's Q1 Adjusted Earnings, Revenue Increase
Zacks
22 days ago
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
Associated Press Finance
22 days ago
MannKind: Q1 Earnings Snapshot
GlobeNewswire
22 days ago
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Compare MNKD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNKD MannKind Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.